Assessment of COVID-19 progression on day 5 from symptoms onset

BMC Infectious Diseases

Table 2 Univariate analysis of laboratory parameters by COVID-19 progression^a

	TOT (n = 235)	Disease progression^a		Univariate
	TOT (n = 235)	No (n = 147)	Yes (n = 88)	OR (95% CI)	p-value
Laboratory parameters
CRP > 80 mg/L	87/196 (44%)	34/124 (27%)	53/72 (74%)	7.38 (3.83 to 14.23)	0.000
NLR > 4.5	104/184 (57%)	54/117 (46%)	50/67 (75%)	3.43 (1.77 to 6.64)	0.000
LDH > 250 U/L	68/104 (65%)	37/69 (54%)	31/35 (89%)	6.70 (2.14 to 21.04)	0.001
CK > 80 U/L	56/102 (55%)	29/66 (44%)	27/36 (75%)	3.83 (1.56 to 9.39)	0.003
ALT > 40 U/L	35/148 (24%)	20/94 (21%)	15/54 (28%)	1.42 (0.66 to 3.09)	0.371
At least 3 abnormal laboratory values^b	66/210 (31%)	29 (22%)	37 (49%)	3.56 (1.93 to 6.56)	0.000

CRP C-reactive protein, NLR neutrophils to lymphocytes ratio, LDH lactate dehydrogenase, CK creatine kinase, AST aspartate aminotransferase, ALT alanine transaminase
^aDisease progression is a composite outcome defined as: death and/or transfer to ICU within day-11 after symptom onset, and/or PaO₂/FiO₂ ratio < 200 on day 10 after symptom onset
^bWithin: CRP > 80 mg/L; NLR > 4.5; LDH > 250 U/L; CK > 80 U/L; ALT > 40 U/L. Results are presented as mean (SD) and mean difference (95% CI) or frequencies (%) and OD (95% CI), as appropriate

ISSN: 1471-2334